Literature DB >> 15997394

Prior vasorelaxation enhances diadenosine polyphosphate-induced contractility of rat mesenteric resistance arteries.

Martin Steinmetz1, Truc Van Le, Stefan Bierer, Jozef Gabriel Rita De Mey, Eberhard Schlatter.   

Abstract

Low-threshold concentrations of diadenosine polyphosphates (ApnA: Ap3A, Ap4A, Ap5A, Ap6A) or ATP, which at basal vessel tone induce just measurable vasoconstrictions, induce up to ten times enhanced vasoconstrictions of previously relaxed (by acetylcholine or sodium nitroprusside or 8Br2 cGMP or isoproterenol or levcromakalim) pre-contracted rat mesenteric resistance arteries (MrA) in a microvessel-myograph. These enhanced vasoconstrictions were of similar magnitude for threshold concentrations of all ApnA.Possibly, the low concentrations of ApnA reverse the prior vasorelaxation by inhibiting a common vasorelaxation pathway, but obviously this is not due to inhibition of guanylate cyclase, which has been previously described to be inhibited by ApnA, because the enhanced vasoconstrictions can be observed with guanylate cyclase-independent vasorelaxants (8Br2 cGMP, isoproterenol or levcromakalim), too. The enhanced vasoconstrictions are endothelium-independent because after mechanical vascular de-endothelialization the results were identical. De-endothelialized vessels, which fail to relax by acetylcholine, showed no enhanced ApnA-induced vasoconstrictions, demonstrating that the mere prior vasorelaxation of the vessel is required to provide the enhanced vasoconstriction by ApnA. Furthermore, the enhanced contractility is not based on a potentiation of the phenylephrine contraction because it equally occurs with other agents used for arterial pre-contraction. Systemically applied ApnA considerably decrease arteriovascular resistance, resulting in hypotension. But here it is demonstrated that a preceding vasorelaxation enables the resistance arteries to generate a strong and persistent ApnA-induced vasoconstriction. Thus, in vivo at very low concentrations ApnA may serve to counteract severe conditions of hypotension (e.g., shock syndrome or anaphylaxis) by the constriction of resistance arteries.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997394     DOI: 10.1007/s00210-005-1059-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  21 in total

1.  Presence of diadenosine 5',5''' -P1, P4-tetraphosphate (Ap4A) in mamalian cells in levels varying widely with proliferative activity of the tissue: a possible positive "pleiotypic activator".

Authors:  E Rapaport; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

2.  Diadenosine 5',5"-P1,P4-tetraphosphate (Ap4A), ATP and catecholamine content in bovine adrenal medulla, chromaffin granules and chromaffin cells.

Authors:  M A Sillero; M Del Valle; E Zaera; P Michelena; A G García; A Sillero
Journal:  Biochimie       Date:  1994       Impact factor: 4.079

3.  Postjunctional synergism of noradrenaline and adenosine 5'-triphosphate in the mesenteric arterial bed of the rat.

Authors:  V Ralevic; G Burnstock
Journal:  Eur J Pharmacol       Date:  1990-01-17       Impact factor: 4.432

4.  Diadenosine polyphosphates cause contraction and relaxation in isolated rat resistance arteries.

Authors:  M Steinmetz; E Schlatter; H A Boudier; K H Rahn; J G De Mey
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

5.  Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney.

Authors:  M van der Giet; M Khattab; J Börgel; H Schlüter; W Zidek
Journal:  Br J Pharmacol       Date:  1997-04       Impact factor: 8.739

6.  Identification and quantification of diadenosine polyphosphate concentrations in human plasma.

Authors:  Joachim Jankowski; Vera Jankowski; Udo Laufer; Markus van der Giet; Lars Henning; Martin Tepel; Walter Zidek; Hartmut Schlüter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-08       Impact factor: 8.311

7.  Vasoactivity of diadenosine polyphosphates in human small mesenteric resistance arteries.

Authors:  Martin Steinmetz; Ann-Kathrin Janssen; Franz Pelster; Karl Heinz Rahn; Eberhard Schlatter
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

8.  The presence of diadenosine 5',5'''-P1,P3-triphosphate (Ap3A) in human platelets.

Authors:  J Lüthje; A Ogilvie
Journal:  Biochem Biophys Res Commun       Date:  1983-08-30       Impact factor: 3.575

9.  Diadenosine phosphates and the physiological control of blood pressure.

Authors:  H Schlüter; E Offers; G Brüggemann; M van der Giet; M Tepel; E Nordhoff; M Karas; C Spieker; H Witzel; W Zidek
Journal:  Nature       Date:  1994-01-13       Impact factor: 49.962

10.  Effects of diadenosine polyphosphates on systemic and regional hemodynamics in anesthetized rats.

Authors:  M Khattab; H Hohage; P Hollah; K H Rahn; E Schlatter
Journal:  Kidney Blood Press Res       Date:  1998       Impact factor: 2.687

View more
  1 in total

1.  Diadenosine tetra- and pentaphosphates affect contractility and bioelectrical activity in the rat heart via P2 purinergic receptors.

Authors:  Ksenia B Pustovit; Vladislav S Kuzmin; Denis V Abramochkin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-17       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.